Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Apr 2025 – Affilogic’s Partner Bracco Imaging published Nanofitins data in Nature Scientific Report : Bracco Imaging has published new data using HER-2 targeting Nanofitins used as diagnostic tool for the management of HER-2 positive tumors.
Mar 2025 – Affilogic’s new publication in Biomolecules : Jacquot & al. – A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice
Around the world
TIDES USA 2025
Affilogic will attend TIDES USA 2025 in San Diego – USA
May 19-22, 2025
BIO Korea 2025
Affilogic will attend BIO Korea 2025 in Seoul – South Korea
May 07-09, 2025
NextGen Biomed UK 2025
Affilogic will present at NextGen Biomed UK 2025 in London – UK
Mar 12-14, 2025
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More